Table 2.
SCRC | MM SCRC | MP SCRC | PM SCRC | PP SCRC | p valuea | |
---|---|---|---|---|---|---|
APC | ||||||
“1st hit” mutation | 33 (44.6) | 10 (62.5) | 6 (37.5) | 9 (37.5) | 7 (38.9) | NS |
“2nd hit” cnLOH | 9 (27.3) | 4 (40.0) | 2 (33.3) | 2 (22.2) | 1 (14.3) | NS |
KRAS | ||||||
“1st hit” mutation | 32 (43.2) | 5 (31.3) | 7 (43.8) | 11 (45.8) | 9 (50.0) | NS |
“2nd hit” cnLOH | – | – | – | – | – | – |
TP53 | ||||||
“1st hit” mutation | 13 (17.6) | 4 (25.0) | – | 4 (16.7) | 5 (27.8) | NS |
“2nd hit” cnLOH | 1 (7.7) | 1 (25.0) | – | 1 (25.0) | – | – |
FBXW7 | ||||||
“1st hit” mutation | 7 (9.5) | 3 (18.8) | 1 (6.3) | 1 (4.2) | 2 (27.8) | NS |
“2nd hit” cnLOH | 1 (14.3) | – | – | – | 1 (50.0) | – |
SMAD4 | ||||||
“1st hit” mutation | 4 (5.4) | 3 (18.8) | – | – | 1 (5.6) | 0.049 |
“2nd hit” cnLOH | – | – | – | – | – | – |
aStatistical analysis was performed by Pearson’s chi square (χ2) test. Parentheses refer to percentage numbers. cnLOH copy neutral loss of heterozygosity, SCRC synchronous colorectal cancer, MM monoclonal monosegmental, MP monoclonal pancolonic, PM polyclonal monosegmental, PP polyclonal pancolonic, NS not significant.